Bayer Schering Pharma AG has filed to initiate a Phase I trial of MN-IC, an antibody-drug conjugate (ADC) for oncology. The move triggers milestone payments to MorphoSys AG and Seattle Genetics. Terms of the payments were not disclosed, but a MorphoSys statement referred to it as “significant.” Bayer Schering licensed Seattle Genetics’ ADC technology with antibodies against target molecule MN, also known as carbonic anhydrase, a tumor-associated antigen expressed in many tum...